![]() | |
![]() Sanofi Genzyme headquarters in Cambridge, Massachusetts in 2007 | |
Company type | Subsidiary |
---|---|
Industry | Biotechnology |
Founded | Boston, Massachusetts (1981) |
Headquarters | , |
Key people | Bill Sibold, Paul Hudson |
Products | Cerezyme Fabrazyme Synvisc Renagel More Complete Product List |
Revenue | US $4.61 billion (2007 calendar)[1] |
![]() | |
![]() | |
Number of employees | 12,000 (2010) |
Parent | Sanofi |
Website | sanofigenzyme |
Genzyme (also known as Genzyme Transgenics Corp or GTC Biotherapeutics) was an American biotechnology company based in Cambridge, Massachusetts. From its acquisition in 2011 to 2022 Genzyme operated as a fully owned subsidiary of Sanofi. In 2010, Genzyme was the world's third-largest biotechnology company, employing more than 11,000 people around the world. As a subsidiary of Sanofi, Genzyme had a presence in approximately 65 countries, including 17 manufacturing facilities and 9 genetic-testing laboratories. Its products were also sold in 90 countries. In 2007, Genzyme generated $3.8 billion in revenue with more than 25 products on the market. In 2006 and 2007, Genzyme was named one of Fortune magazine’s “100 Best Companies to Work for”. The company donated $83 million worth of products worldwide; in 2006, it made $11 million in cash donations. In 2005, Genzyme was awarded the National Medal of Technology, the highest level of honor awarded by the president of the United States to America's leading innovators.[2] In February 2022, Sanofi's new corporate brand was unveiled and former entity "Sanofi Genzyme" got integrated into Sanofi.[3][4]